Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rhythm Pharmaceuticals, Inc. (RYTM) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing structured access to its public reporting. Rhythm is a commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, and its filings offer insight into the development and commercialization of IMCIVREE (setmelanotide) and related MC4R agonist programs.
Investors can review current reports on Form 8‑K in which Rhythm discusses material events such as quarterly and annual financial results, FDA and EMA regulatory milestones, equity offerings, and amendments to its certificate of incorporation. For example, the company has filed 8‑Ks describing FDA Priority Review and PDUFA goal dates for a supplemental New Drug Application for IMCIVREE in acquired hypothalamic obesity, as well as an 8‑K detailing an underwritten public offering of common stock and intended use of proceeds.
While this page focuses on current reports and other SEC documents, it also serves as a gateway to Rhythm’s periodic reports, where investors typically find detailed information on revenue from global sales of IMCIVREE, research and development expenses, selling, general and administrative expenses, cash position and funding runway. These filings also describe clinical programs in acquired and congenital hypothalamic obesity, genetically caused MC4R pathway diseases and Prader-Willi syndrome, along with investigational agents bivamelagon and RM-718.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, such as changes in operating expenses, financing transactions, or significant regulatory updates. Real-time ingestion from EDGAR helps surface new Rhythm filings quickly, and users can also monitor items that may relate to executive or director activity when Forms 3, 4 or 5 are filed. This combination of original documents and AI explanations is designed to make RYTM’s complex biopharmaceutical disclosures more accessible to a broad range of investors.
Rhythm Pharmaceuticals (RYTM) reported an insider transaction by Chief Technical Officer Joseph Shulman. On 10/28/2025, he exercised employee stock options for 2,094 shares at an exercise price of $27.35 and 721 shares at $30.66, then sold 2,815 shares of common stock at a weighted average price of $115.0089. The sale was made pursuant to a Rule 10b5‑1 trading plan adopted on August 8, 2024.
Following these transactions, Shulman beneficially owned 8,509 shares directly. The filing notes the sales occurred in multiple trades between $115.00 and $115.08. The option grant dated February 1, 2023 vests in 16 substantially equal quarterly installments, and another option referenced is fully vested. Derivative holdings reported after the transactions include option positions totaling 12,563 and 9,748 underlying shares, respectively.
Rhythm Pharmaceuticals (RYTM) reported insider activity by its Chief Technical Officer. On 10/16/2025, the officer exercised stock options for 2,093 shares at $27.35 and 12,344 shares at $30.66, then sold 2,693 shares at a weighted average $110.9482, 8,332 shares at $112.0554, and 3,412 shares at $112.81. The trades were made under a Rule 10b5-1 plan adopted on August 8, 2024. Following the transactions, the officer reported 8,509 shares beneficially owned directly. Option holdings reported after the exercises were 14,657 (at $27.35) and 10,469 (at $30.66).
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, reported changes in his beneficial ownership on Form 4. On 09/02/2025 he acquired 2,094 shares by exercising options with an exercise price of $27.35 and acquired 14,687 shares by exercising options with an exercise price of $30.66, bringing his post-transaction common stock holdings to 25,290 shares (direct). The filing also reports a sale of 16,781 shares on the same date under a Rule 10b5-1 instruction adopted August 8, 2024, at a weighted-average sale price of $105.298, leaving 8,509 shares owned after the sale. Option grants referenced were dated February 1, 2023 and February 11, 2021 with multi-period vesting schedules.
Rhythm Pharmaceuticals, Inc. (RYTM) reported a Form 144 notice for the proposed sale of 16,781 shares of common stock through Morgan Stanley Smith Barney LLC on 09/02/2025, with an indicated aggregate market value of $1,730,960.15 and total shares outstanding listed as 66,420,091. The filing states these shares were acquired on 09/02/2025 via exercise of stock options and paid in cash on the same date.
The filer also disclosed three 10b5-1 sales by Joseph J. Shulman in the past three months: 4,188 shares on 08/21/2025 (gross proceeds $419,090.86), 3,984 shares on 08/11/2025 (gross proceeds $358,891.47), and 7,969 shares on 07/09/2025 (gross proceeds $619,850.56).
Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals (RYTM), reported option exercise and subsequent sale on 08/21/2025. He exercised 4,188 stock options with an exercise price of $27.35, which converted into 4,188 shares of common stock. Those shares were sold the same day pursuant to a Rule 10b5-1 instruction adopted on August 8, 2024, in multiple transactions at a weighted average price of $100.0694 per share (individual sale prices ranged from $100.00 to $100.30). Following the reported transactions, Mr. Shulman beneficially owned 8,509 shares of common stock and held 18,844 shares underlying outstanding options.
Rhythm Pharmaceuticals (RYTM) Form 144 notice reports a proposed sale of 4,188 common shares by an insider through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $413,355.60. The filing shows these shares were acquired on 08/21/2025 by exercise of stock options and paid for in cash the same day. The issuer has 66,420,091 shares outstanding, so the proposed sale represents a small fraction of total shares. The filer also reported two prior 10b5-1 sales by the same person in the past three months: 3,984 shares sold on 08/11/2025 for $358,891.47 and 7,969 shares sold on 07/09/2025 for $619,850.56. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported option exercises and share sales on August 12-13, 2025. The filing shows Mr. Smith exercised 24,611 stock options at an exercise price of $6.88 on August 12, 2025, and 3,477 options at the same exercise price on August 13, 2025, resulting in 28,088 shares underlying those exercises.
Concurrent with the August 12 exercise, 24,611 shares were sold under a Rule 10b5-1 plan at a weighted-average price of $96.3322 per share (individual sale prices ranged $96.00–$96.63). On August 13, 3,477 shares were sold at $96.00 per share. After these transactions the reporting person owned 116,915 shares beneficially. The Form 4 notes the 10b5-1 plan was adopted February 28, 2025, and the stock options were fully vested.
Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals (RYTM), reported buy and sell transactions on 08/12/2025. The Form 4 shows acquisitions of 1,000 shares at $17.97 and 500 shares at $49.23, and a sale of 1,500 shares at $95. Following these transactions, the reporting person beneficially owned 922 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 11, 2025. The filing also discloses outstanding stock options: 1,000 options (exercise price $17.97) exercisable beginning 04/03/2033 and 500 options (exercise price $49.23) exercisable beginning 02/15/2034, with detailed vesting schedules provided.
RA Capital and affiliated persons reported ownership of 5,561,359 shares of Rhythm Pharmaceuticals, Inc. common stock, equal to 8.7% of the class based on 63,621,472 shares outstanding as of April 30, 2025. The filing lists the Fund (RA Capital Healthcare Fund, L.P.) as the direct holder of the 5,561,359 shares and states that RA Capital Management, L.P. serves as the Fund's investment adviser with delegated sole power to vote and dispose of the Fund's holdings, although the Fund disclaims beneficial ownership for Section 13(d) purposes because that delegation may not be revoked on less than 61 days' notice. The Reporting Persons expressly disclaim status as a group. The filing includes the issuer's principal office address in Boston and signatures dated 08/14/2025.
Primecap Management Co./CA reports beneficial ownership of 4,878,037 shares of Rhythm Pharmaceuticals, representing 7.67% of the common stock. The filing is an Amendment No. 10 to a Schedule 13G and lists an event date of 06/30/2025. Primecap reports sole voting and sole dispositive power over these shares, and certifies the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. The filing names Rhythm Pharmaceuticals' principal executive offices at the address provided and shows Primecap's business address in Pasadena, California. The form is signed by Jorge A. Rodriguez, Deputy Chief Compliance Officer, dated 08/13/2025.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
